Jarman M - Search Results

1

Analogues of tamoxifen: the role of the basic side-chain. Applications of a whole-cell oestrogen-receptor binding assay to N-oxides and quaternary salts.

Jarman M, Leung OT, Leclercq G, Devleeschouwer N, Stoessel S, Coombes RC, Skilton RA. Jarman M, et al. Anticancer Drug Des. 1986 Nov;1(3):259-68. Anticancer Drug Des. 1986. PMID: 3450298

2

Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen.

McCague R, Parr IB, Leclercq G, Leung OT, Jarman M. McCague R, et al. Among authors: jarman m. Biochem Pharmacol. 1990 May 1;39(9):1459-65. doi: 10.1016/0006-2952(90)90427-m. Biochem Pharmacol. 1990. PMID: 2334445

3

Non-isomerisable antiestrogens related to tamoxifen.

McCague R, Jarman M, Leung OT, Foster AB, Leclercq G, Stoessel S. McCague R, et al. Among authors: jarman m. J Steroid Biochem. 1988 Oct;31(4B):545-7. doi: 10.1016/0022-4731(88)90005-2. J Steroid Biochem. 1988. PMID: 3199805

4

Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.

Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC. Chander SK, et al. Among authors: jarman m. Cancer Res. 1991 Nov 1;51(21):5851-8. Cancer Res. 1991. PMID: 1933854

5

Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent.

McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, Foster AB. McCague R, et al. Among authors: jarman m. J Med Chem. 1989 Dec;32(12):2527-33. doi: 10.1021/jm00132a006. J Med Chem. 1989. PMID: 2585441

6

Hydroxy derivatives of tamoxifen.

Foster AB, Jarman M, Leung OT, McCague R, Leclercq G, Devleeschouwer N. Foster AB, et al. Among authors: jarman m. J Med Chem. 1985 Oct;28(10):1491-7. doi: 10.1021/jm00148a020. J Med Chem. 1985. PMID: 4045924

7

Antagonism of estrogen receptor and calmodulin association by antiestrogens is not dependent on an interaction with calmodulin.

Rowlands MG, Grimshaw R, Jarman M, Bouhoute A, Leclercq G. Rowlands MG, et al. Among authors: jarman m. Biochem Pharmacol. 1997 Jan 24;53(2):241-4. doi: 10.1016/s0006-2952(96)00603-x. Biochem Pharmacol. 1997. PMID: 9037257

8

Length increase of the side chain of idoxifene does not improve its antagonistic potency in breast-cancer cell lines.

Jin L, Legros N, Leclercq G, Hardcastle IR, Jarman M. Jin L, et al. Among authors: jarman m. Cancer Chemother Pharmacol. 1998;41(4):339-42. doi: 10.1007/s002800050748. Cancer Chemother Pharmacol. 1998. PMID: 9488604

9

4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer.

Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M, Brodie AM. Coombes RC, et al. Among authors: jarman m. Steroids. 1987 Jul-Sep;50(1-3):245-52. doi: 10.1016/0039-128x(83)90075-2. Steroids. 1987. PMID: 3504062

10

Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts.

Pace P, Jarman M, Phillips D, Hewer A, Bliss J, Coombes RC. Pace P, et al. Among authors: jarman m. Br J Cancer. 1997;76(6):700-4. doi: 10.1038/bjc.1997.449. Br J Cancer. 1997. PMID: 9310233 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299 results

Search Page

Filters